• Sino Biopharmaceutical’s TQB2102 won a third Breakthrough Therapy Designation from China’s CDE for chemo-naïve unresectable or metastatic HER2-low breast cancer.
• The HER2 bispecific antibody-drug conjugate is in multiple Phase III trials, including chemotherapy-naïve advanced HER2-low breast cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260803-12267202), on August 03, 2026, and is solely responsible for the information contained therein.